3-Methoxy-4-Hydroxyphenylglycol - Explore the Science & Experts | ideXlab


Scan Science and Technology

Contact Leading Edge Experts & Companies

3-Methoxy-4-Hydroxyphenylglycol

The Experts below are selected from a list of 71214 Experts worldwide ranked by ideXlab platform

3-Methoxy-4-Hydroxyphenylglycol – Access All Experts and Articles

Erik G Jonsson – One of the best experts on this subject based on the ideXlab platform.

  • polymorphisms in genes implicated in dopamine serotonin and noradrenalin metabolism suggest association with cerebrospinal fluid monoamine metabolite concentrations in psychosis
    Behavioral and Brain Functions, 2014
    Co-Authors: Dimitrios Andreou, Erik G Jonsson, Erik Soderman, Tomas Axelsson, Goran Sedvall, Lars Terenius, Ingrid Agartz

    Abstract:

    Background
    Homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA) and 3-Methoxy-4-Hydroxyphenylglycol (MHPG) are the major monoamine metabolites in the central nervous system (CNS). Their cerebrospinal fluid (CSF) concentrations, reflecting the monoamine turnover rates in CNS, are partially under genetic influence and have been associated with schizophrenia. We have hypothesized that CSF monoamine metabolite concentrations represent intermediate steps between single nucleotide polymorphisms (SNPs) in genes implicated in monoaminergic pathways and psychosis.

  • Brain-derived neurotrophic factor gene variation influences cerebrospinal fluid 3-Methoxy-4-Hydroxyphenylglycol concentrations in healthy volunteers.
    Journal of Neural Transmission, 2008
    Co-Authors: Erik G Jonsson, Dimitrios Andreou, Goran Sedvall, Ingrid Agartz, Peter Saetre, Bodil Edman-ahlbom, Anna Sillén, Agneta Gunnar, Håkan Hall, Lars Terenius

    Abstract:

    Brain-derived neurotrophic factor (BDNF) has been shown to influence monoamine transmitter synthesis, metabolism and release. We investigated possible relationships between four BDNF gene polymorphisms and cerebrospinal fluid (CSF) concentrations of 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA), and 3-Methoxy-4-Hydroxyphenylglycol (MHPG) in healthy volunteers (n = 132). All BDNF polymorphisms (270 C/T, −633 T/A, Val66Met, and 11757 G/C) were associated with MHPG (P < 0.02), but not with 5-HIAA and HVA concentrations. At a second clinical investigation 8–20 years after CSF sampling 30% of the subjects had experienced various psychiatric disorders. Development of a psychiatric disorder was predicted by low 5-HIAA concentrations (P = 0.01). The results suggest that BDNF gene variation participates in regulation of norepinephrine turnover rates in the central nervous system of human subjects.

W E Muller – One of the best experts on this subject based on the ideXlab platform.

  • the influence of total sleep deprivation on urinary excretion of catecholamine metabolites in major depression
    Acta Psychiatrica Scandinavica, 1993
    Co-Authors: H U Muller, Dieter Riemann, Mitchel S Berger, W E Muller

    Abstract:

    To elucidate the influence of total sleep deprivation (TSD) on catecholaminergic neurotransmission, which is assumed to be disturbed in depression, 9 depressive patients collected consecutive 24-h urine samples prior to (baseline), during (TSD) and following total sleep deprivation (post-TSD). Urine samples were analysed for total MHPG (3-Methoxy-4-Hydroxyphenylglycol), conjugates of MHPG (glucuronide and sulfate), excretion of HVA (homovanillic acid) and VMA (3-methoxy-4-hydroxymandelic acid). TSD increased the urinary excretion of MHPG-sulfate as a marker of the central norepinephrine metabolism and the excretion rates of VMA and HVA as indices of the peripheral catecholamine metabolism. Patients with higher VMA values prior to TSD reacted worse, and the VMA increase due to TSD was positively correlated with the response. The results demonstrate that TSD, besides acting as a stimulus on the peripheral sympathetic nervous system, influences central nervous noradrenergic neurotransmission, as reflected by the increase of MHPG-sulfate.

Jun Nakamura – One of the best experts on this subject based on the ideXlab platform.

  • Serum levels of brain-derived neurotrophic factor (BDNF), proBDNF and plasma 3-Methoxy-4-Hydroxyphenylglycol levels in chronic schizophrenia.
    Annals of General Psychiatry, 2016
    Co-Authors: Reiji Yoshimura, Hikaru Hori, Kiyokazu Atake, Asuka Katsuki, Jun Nakamura

    Abstract:

    Background
    We investigated the serum levels of brain-derived neurotrophic factor (BDNF), proBDNF and plasma 3-Methoxy-4-Hydroxyphenylglycol (MHPG) levels in patients with chronic schizophrenia.

  • Serum levels of brain-derived neurotrophic factor (BDNF), proBDNF and plasma 3-Methoxy-4-Hydroxyphenylglycol levels in chronic schizophrenia
    Annals of General Psychiatry, 2016
    Co-Authors: Reiji Yoshimura, Hikaru Hori, Kiyokazu Atake, Asuka Katsuki, Jun Nakamura

    Abstract:

    Background We investigated the serum levels of brain-derived neurotrophic factor (BDNF), proBDNF and plasma 3-Methoxy-4-Hydroxyphenylglycol (MHPG) levels in patients with chronic schizophrenia. Methods Sixty-eight patients who met the DSM-IV-TR criteria and had a chronic schizophrenia (CS) duration of ≥ 5 years were enrolled. Their serum brain-derived BDNF and proBDNF levels were measured by enzyme-linked immunosorbent assays, and their plasma MHPG levels were analyzed by high-performance liquid chromatography with electrochemical detection. Results The plasma MHPG levels were significantly lower in the CS group (3.9  ±  1.8 ng/ml) compared to those in the group of 32 age- and sex-matched healthy controls (5.1  ±  2.4 ng/ml). The serum BDNF levels were significantly lower in the CS group (8.9  ±  4.8 ng/ml) compared to the control group (12.2.1  ±  6.8 ng/ml). No correlation was observed between plasma MHPG and BDNF in the CS group. Conclusion These results suggest that hypo-activity of noradrenergic neurons and decreased BDNF secretion exist in chronic schizophrenic patients.

  • Duloxetine, a Selective Noradrenaline Reuptake Inhibitor, Increased Plasma Levels of 3-Methoxy-4-Hydroxyphenylglycol but Not Homovanillic Acid in Patients with Major Depressive Disorder.
    Clinical Psychopharmacology and Neuroscience, 2014
    Co-Authors: Kiyokazu Atake, Hikaru Hori, Reiji Yoshimura, Asuka Katsuki, Atsuko Ikenouchi-sugita, Wakako Umene-nakano, Jun Nakamura

    Abstract:

    OBJECTIVE We investigated the effects of duloxetine on the plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor (BDNF) in 64 patients with major depressive disorder (MDD). METHODS Major depressive episode was diagnosed using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders-fourth edition (DSM-IV) according to the DSM-IV text revision (DSM-IV-TR) criteria. The severity of depression was evaluated using the 17-item Hamilton Rating Scale for Depression (HAMD-17). Blood sampling and clinical evaluation were performed on days 0, 28, and 56. RESULTS Duloxetine treatment for 8 weeks significantly increased the plasma 3-Methoxy-4-Hydroxyphenylglycol (MHPG) levels but not the homovanillic acid (HVA) levels in responders with MDD. CONCLUSION These results imply that noradrenaline plays an important role in alleviating depressive symptoms.